Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lowered its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 9.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 429,392 shares of the company’s stock after selling 42,344 shares during the period. Janux Therapeutics accounts for 2.8% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s investment portfolio, making the stock its 17th largest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Janux Therapeutics were worth $22,990,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $139,000. Meeder Asset Management Inc. acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $159,000. Tower Research Capital LLC TRC increased its holdings in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in Janux Therapeutics in the fourth quarter valued at approximately $221,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $2,464,170. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 in the last three months. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Trading Down 0.5%

Janux Therapeutics stock opened at $24.17 on Tuesday. The stock has a fifty day moving average price of $28.50 and a 200 day moving average price of $40.33. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The firm has a market capitalization of $1.43 billion, a P/E ratio of -20.66 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JANX shares. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank lowered their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. Finally, Wedbush restated an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.